Redeye provides its comment on Mendus’ Q1 2024 report. Encouragingly, the company has recently received the ethics committee greenlight for CADENCE, and we understand the trial initiated patient recruitment in April 2024. TO3 exercise has extended Mendus’ funding runway into Q3 2025e, i.e., beyond CADENCE part 1 top-line data (mid-2025e). We finetune our estimates and valuation.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Mendus Q1 2024 - Funded until next major catalyst

© Modular Finance, source Nordic Press Releases